RATIONALE 001: Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy in patients (pts) with newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 30; p. ii67
Main Authors Paz-Ares, L., Senan, S., Planchard, D., Wang, L., Cheong, A., Slepetis, R., Nguyen, M.H., Vokes, E.E.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2019
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdz063.083